|Horizon Pharma, Inc.|
520 Lake Cook Road
United States - Map
Horizon Pharma, Inc., a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. The company offers DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications. It also provides LODOTRA/RAYOS, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active rheumatoid arthritis in adults when accompanied by morning stiffness, as well as approved for the treatment of polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, and other conditions. The company was founded in 2005 and is headquartered in Deerfield, Illinois.
|Horizon Pharma, Inc.’s ISS Governance QuickScore as of Jun 1, 2013 is 7. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Timothy P. Walbert ,
Chairman, Chief Exec. Officer, Pres, Chief Exec. Officer of Horizon Pharma USA, Pres of Horizon Pharma USA and Director of Horizon Pharma USA
|Mr. Robert J. De Vaere ,
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Sec.
|Dr. Jeffrey W. Sherman M.D., F.A.C.P.,
Chief Medical Officer and Exec. VP of Devel., Regulatory Affairs & Manufacturing
|Mr. Michael Adatto ,
Sr. VP of Managed Care and Commercial Devel.
|Mr. Todd N. Smith ,
Chief Commercial Officer and Exec. VP
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|